You are here: Industry Insights > Takeda

News List

Takeda’s Osaka headquarters up for sale as drugmaker funds $62B Shire buyout fiercepharma
July 06, 2018
It’s no secret that Takeda is taking on a huge debt load to make the $62 billion Shire acquisition happen. Now, it’s looking to fill some of the financial gap by selling its old headquarters in Osaka, Japan.
Takeda's Entyvio secures Japanese approval in ulcerative colitis pharmafile
July 06, 2018
As one of the most common forms of inflammatory bowel disease (IBD), ulcerative colitis affects over 220,000 people in Japan.
Takeda to sell Osaka site to soften Shire deal's financial impact pharmafile
July 06, 2018
It’s one of the biggest acquisitions the industry has seen at a total value of $63 billion and after weeks of agonising negotiation and rejection,
Where do big-cap biopharmas stand on the M&A matrix? fiercepharma
May 30, 2018
Johnson & Johnson has the most bucks for biopharma M&A, Astellas the easiest target: analyst
Takeda divests Chinese JV for $280M after reaching Shire deal fiercebiotech
May 29, 2018
Takeda's $62 billion acquisition of Shire will vault it into the 10 pharma companies worldwide, but will also saddle it with a substantial debt load.
Takeda begins to shore up finances with $280m divestment pharmafile
May 25, 2018
Much has already been written about Takeda and its massive financial stretch to pull in the Shire acquisition, in the massive $62 billion deal.
Takeda Divests Techpool to Joint-Venture Partners in China biospectrumasia
May 22, 2018
Techpool’s portfolio of innovative medicines include: Roan (Ulinastatin for Injection), a treatment for acute and chronic pancreatitis, Kallikrein for mid-moderate acute thrombotic cerebral infarction, and Kailikang
Takeda financials show why the Shire deal was needed pharmafile
May 15, 2018
After posting its financials from 2017 and its guidance for the year to come, it’s clear to see why Takeda needed to inject some growth into the company through its mega-merger with Shire.
Takeda to vault into Big Pharma with $62B Shire buyout—and megamerger cuts are on the way fiercepharma
May 09, 2018
After weeks of bidding, the Japanese drugmaker agreed to shell out $62 billion on the rare disease specialist, 46% cash, 54% stock—roughly the same terms Takeda disclosed when it announced its fifth bid. The deal will vault Takeda into the top 10 pharma c
Thermo Fisher inks deals with Daiichi and Takeda biospectrumasia
May 03, 2018
Thermo Fisher Scientific has entered into agreements with Daiichi Sankyo and Takeda Pharmaceutical aimed at expanding the utility of its Oncomine Dx Target Test to support each firm's clinical trials and development programs.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page